About Us
Hedera Dx is dedicated to transforming oncology care by providing cutting-edge in-house cancer testing solutions that improve patient outcomes as well as healthcare professional experiences, while facilitating the prescription and development of the next breakthrough oncology therapies.
Clinicogenomics evidence entirely dedicated to global decentralized oncology care
Hedera Dx provides unique real-world data from a decentralized global network, enabling informed decision-making and accelerating the development of next-generation personalized cancer therapies.
Unique customer experience
At Hedera Dx, we are committed to providing a unique customer experience by partnering with laboratories and clinicians to offer fast, locally CE-IVDR compliant and clinically actionable NGS-based liquid biopsies solutions to be processed in-house. Our approach aims at becoming a global provider of both analytically & clinically validated liquid biopsy tests processed in daily practice, in accordance with guidelines and regulatory-approved cancer therapy options.
We’re united by a vision to make modern cancer care globally accessible
Hedera Dx is transforming oncology care globally by enabling routine use of advanced in-house NGS solutions, removing hurdles to adopt solutions that drive better therapy options and outcomes for cancer patients.
A Patient-Driven Approach
By actively engaging patients via myHedera app and their early involvement in our studies, they become catalysts for personalized care and transformative advancements. Their participation enables them to shape their own outcomes and experiences, while also contributing valuable insights. Through the integration of Patient-Reported Outcomes (PROs) and Patient-Reported Experience Measures (PREMs), patients provide a holistic perspective on their journey, encompassing their unique lived experiences in addition to clinical and genomic insights provided by investigators. This collaborative approach places patients at the center of their own care, fostering a deeper understanding between healthcare providers, researchers, and individuals. Eventually, this patient-centric initiative aims at driving better oncology care practices and meaningful progress in personalized medicine, propelling the field towards patient-centered excellence.
By offering a range of liquid biopsy solutions, we enable cancer patients to access non-invasive blood-based diagnostics tests that facilitate better, timely treatment options selection to ultimately improve their experiences and quality of life.
Beyond our commitment to develop liquid biopsy solutions, we also strive to continuously deliver compelling patient support tools and programs (e.g. patients apps) that help understand, treat, and monitor cancer, to enable patients to live longer and better lives.
Testimonials
“To date, liquid biopsy has not always been used in clinical routine by molecular laboratories due to time intensive workflows (e.g. regulatory compliance, (bio)informatics and reporting hurdles). Hedera Dx next-generation sequencing solution brings new possibilities to accelerate global adoption of liquid biopsies by matching patients’ tumor with regulatory approved therapies quickly and efficiently, as more and more biomarkers get identified and recommended by international guidelines for better patient outcome.”
Testimonials
“To date, liquid biopsy has not always been used in clinical routine by molecular laboratories due to time intensive workflows (e.g. regulatory compliance, (bio)informatics and reporting hurdles). Hedera Dx next-generation sequencing solution brings new possibilities to accelerate global adoption of liquid biopsies by matching patients’ tumor with regulatory approved therapies quickly and efficiently, as more and more biomarkers get identified and recommended by international guidelines for better patient outcome.”
Testimonials
“To date, liquid biopsy has not always been used in clinical routine by molecular laboratories due to time intensive workflows (e.g. regulatory compliance, (bio)informatics and reporting hurdles). Hedera Dx next-generation sequencing solution brings new possibilities to accelerate global adoption of liquid biopsies by matching patients’ tumor with regulatory approved therapies quickly and efficiently, as more and more biomarkers get identified and recommended by international guidelines for better patient outcome.”
Team
Backed by leading investors, Hedera Dx was established in Switzerland in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel. Today our team spans eight countries, specializing in field application work, computational methods, software engineering, commercial expertise, molecular biology, data management and artificial intelligence.
Tommi Lehtonen
CEO, Co-founder
An experienced genetics entrepreneur who previously co-founded and grew Blueprint Genetics into a global provider of genetic testing for hereditary and rare diseases. Prior to Hedera Dx, Tommi led the Specialty Genetics clinical franchise at Quest Diagnostics as VP/GM.
Christian Meisel
CMO, Co-founder, MD PhD
Christian has a 20-year+ career in precision oncology, as a physician and from key senior executive positions at Roche, such as Global Head Translational Medicine, Global Head Biomarkers and Personalized Healthcare Platforms, and helping cancer patients as the CMO of Molecular Health.
Damien Lapray
CCO, Co-founder, PhD
Deeply rooted in the hospital laboratory world, Damien was previously the long-standing CCO of Sophia Genetics, growing and managing the entire commercial operation of Sophia Genetics and working broadly with the genetics community globally.
Frances Rhodius Sagnier
CFO
Fran oversees all things finance and operations, building on her background in finance roles at Sophia Genetics and J.P. Morgan. Fran is known for analytical acumen, ability to get things done, optimization mindset and leadership to drive both top and bottom lines.
Kaarlo Haikonen
Director Engineering & Product
A highly skilled software developer turned engineering leader who co-founded Kaiku Health, a platform enabling digital monitoring of symptoms in cancer care, used in clinical routine by thousands of patients globally. Prior to Hedera Dx, Kaarlo built teams to develop next-generation product initiatives at Elekta, working closely with the broader oncology community.
Sanga Mitra Boppudi
Director Assay Development, PhD
Leading expert in genomic research, with over a decade of experience in Next Generation Sequencing (NGS) technologies. In her former role as a laboratory head, Sanga Mitra developed a broad range of NGS applications, including assay and panel designs, applied to many R&D and oncology clinical projects.
Thomas Vetterli
Director Bioinformatics & ML
Thomas is a passionate machine learning leader with a Bay Area background from Freenome and Berkeley Lights. He brings a wealth of knowledge from computational methods research and building large-scale platforms that integrate machine learning and bioinformatics to process data for liquid biopsy applications.
Raman Ghuman
VP of Commercial Partnerships
Raman Ghuman is VP of Commercial Partnerships at Hedera Dx, leading pharma strategy and collaborations with biopharma and research organizations to deliver real-world data partnerships. With over a decade of experience in oncology and real-world data, he was previously Head of Partnerships for Europe at Owkin and held senior roles at TriNetX. At Hedera Dx, he focuses on advancing clinico-genomic programmes with customers and the generation of real-world evidence to support clinical development and precision medicine.
Paola Castelli
Vice President of Sales
Paola brings 15+ years of experience in genomics and high-throughput DNA sequencing, having worked in leading international sales & business development roles at GE Healthcare and Sophia Genetics. Highly knowledgeable in sequencing technologies, Paola excels in strategic account development, building partnerships with KOLs and distributors, and nurturing global sales talent.
Culture
Our team is passionate about the work we do and why we do it
Our culture is based on thinking differently, being ambitious, being benevolent and being human, basically being ourselves. This goes into everything we do: from how we develop our products, how we work, and who we hire. Beyond the complexity and seriousness of what we aim to solve, we make sure to enjoy what we do on a daily basis, how we work together and celebrate our success as a team.
Careers
Want to be a part of our team?
Join the mission
Make real impact and join our team of talented individuals
Open application
Hedera Dx is committed to fostering an inclusive, respectful, and equitable workplace. Our Gender Equality Plan (GEP) outlines concrete actions to promote equal opportunities across recruitment, career development, leadership representation, and workplace culture. As an early-stage biotech company, we implement practical measures, including flexible work practices, bias-aware hiring processes, annual diversity training, and transparent monitoring of gender-related workforce data. We also integrate gender considerations into research and innovation where scientifically relevant and maintain a zero-tolerance approach to harassment or discrimination. Through continuous monitoring and leadership commitment, Hedera Dx aims to build a collaborative environment where all employees can thrive and contribute equally.